Your browser is no longer supported. Please, upgrade your browser.
Reneo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.43 Insider Own0.20% Shs Outstand24.40M Perf Week17.12%
Market Cap187.34M Forward P/E- EPS next Y-2.84 Insider Trans197.41% Shs Float23.74M Perf Month-13.06%
Income-33.60M PEG- EPS next Q-0.47 Inst Own75.30% Short Float1.18% Perf Quarter-23.10%
Sales- P/S- EPS this Y-56.50% Inst Trans0.32% Short Ratio6.55 Perf Half Y-31.00%
Book/sh6.40 P/B1.15 EPS next Y7.20% ROA- Target Price34.75 Perf Year-
Cash/sh6.22 P/C1.19 EPS next 5Y- ROE- 52W Range5.95 - 17.18 Perf YTD-46.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.98% Beta-
Dividend %- Quick Ratio25.60 Sales past 5Y- Gross Margin- 52W Low24.20% ATR0.75
Employees13 Current Ratio25.60 Sales Q/Q- Oper. Margin- RSI (14)50.97 Volatility12.64% 9.49%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.53 Prev Close7.40
ShortableYes LT Debt/Eq0.00 EarningsNov 12 BMO Payout- Avg Volume42.83K Price7.39
Recom1.30 SMA20-2.38% SMA502.63% SMA200-18.22% Volume22,889 Change-0.14%
Nov-22-21Initiated Ladenburg Thalmann Buy $45
May-04-21Initiated SVB Leerink Outperform $25
May-04-21Initiated Piper Sandler Overweight $45
May-04-21Initiated Jefferies Buy $24
Nov-11-21 04:05PM  
Nov-01-21 04:05PM  
Oct-14-21 08:00AM  
Oct-11-21 02:35PM  
Sep-28-21 08:26AM  
Sep-09-21 09:12AM  
Aug-11-21 05:55AM  
Jul-28-21 08:00AM  
Jul-12-21 09:30AM  
Jul-09-21 08:00AM  
Jul-07-21 08:00AM  
Jun-29-21 08:00AM  
May-20-21 06:00AM  
May-19-21 06:00AM  
Apr-13-21 08:14AM  
Apr-09-21 12:32PM  
Apr-08-21 09:42PM  
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jindal Vineet R.Chief Financial OfficerAug 25Buy7.445,00037,1765,000Aug 26 05:54 PM
FLESHER GREGORY J.President and CEOAug 25Buy8.008,00064,0008,000Aug 26 05:52 PM
Cruse MichaelSenior VP-Corporate OperationsAug 25Buy7.452,50018,6162,500Aug 26 05:51 PM
Muralidhar BaliDirectorJul 14Buy8.50111,736949,7562,073,957Jul 15 05:34 PM
Johnson Wendy S.Chief Development OfficerJul 14Sale8.50111,736949,7560Jul 15 05:33 PM
Johnson Wendy S.Chief Development OfficerJul 08Option Exercise1.97111,736220,120111,736Jul 09 06:52 PM
Muralidhar BaliDirectorJun 23Buy9.2820,710192,2451,962,221Jun 25 09:00 AM
Muralidhar BaliDirectorJun 22Buy8.7214,615127,4871,941,511Jun 23 08:33 AM
Muralidhar BaliDirectorJun 21Buy9.0332,659294,9271,926,896Jun 23 08:33 AM
Muralidhar BaliDirectorJun 08Buy9.5016,605157,7091,894,237Jun 10 09:00 AM
Muralidhar BaliDirectorJun 04Buy9.422572,4221,877,632Jun 07 08:53 AM
Muralidhar BaliDirectorJun 03Buy9.2512,100111,9431,877,375Jun 07 08:53 AM
Muralidhar BaliDirectorMay 28Buy9.50141331,865,275Jun 02 10:37 AM
Muralidhar BaliDirectorMay 27Buy9.261,12010,3691,865,261May 28 04:10 PM
Muralidhar BaliDirectorMay 26Buy9.385,91555,4951,864,141May 28 04:10 PM
New Enterprise Associates 15, 10% OwnerApr 13Buy15.00666,6669,999,9904,785,494Apr 15 06:16 PM
O'Donnell NiallDirectorApr 13Buy15.00200,0003,000,0002,063,713Apr 15 04:16 PM
Muralidhar BaliDirectorApr 13Buy15.00200,0003,000,0001,858,226Apr 15 04:15 PM
Novo Holdings A/S10% OwnerApr 13Buy15.00666,6669,999,9903,430,377Apr 14 04:44 PM
RiverVest Venture Fund III, L.10% OwnerApr 09Buy15.00200,0003,000,0002,409,220Apr 13 05:54 PM